(Reuters) - Merck & Co on Monday said it expects next year to seek U.S. approval for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary effectiveness goals in a late-stage trial.
via Reuters: Health News Read More Here..
No comments:
Post a Comment